Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 6, 2025
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Enzyme activity studied under new lens!

How does the rice blast fungus invade its host cells?

First interchangeable biosimilar insulin for diabetic patients

Enzyme activity studied under new lens!
  • BiotechToday
  • World

Enzyme activity studied under new lens!

bioxone August 2, 2021August 1, 2021

Shenade Annie Kerketta, Amity University Kolkata

The knowledge that we have about how an enzyme works is through studying its ACTIVE SITE. New technology has been developed that gives us information about an enzyme by studying beyond the active site. The new technology is called HIGH THROUGHPUT MICROFLUIDIC ENZYME KINETICS (HT-MEK). This technology combines two processes which this article will describe.

What are enzymes?

Enzymes are biomolecules that alter the rate of reaction occurring inside an organism. They are, termed BIOCATALYSTS because they speed up the reaction inside a living organism. Without them, no metabolic activity would take place because the reactions would slow down considerably. They act as fuel for the body. Majority of them are made up of amino acids.

The mechanism behind enzyme activity:

ENZYME + SUBSTRATE → ENZYME-SUBSTRATE COMPLEX → ENZYME PRODUCT COMPLEX→ DESIRED PRODUCT + FREE ENZYME.

Here, the substrate depicts the substance on which the enzyme is acting. An enzyme has a specific structure that is essential for its working. An enzyme’s function depends upon its structure. If the structure changes, so do the function. The sequence of amino acids determines an enzyme’s structure. The site of an enzyme that binds to the substrate is called BINDING SITE. The site, which carries out the catalytic function is called CATALYTIC SITE. The binding site and catalytic site together form the ACTIVE SITE.

The active site is where the substrate binds. It contains residues that hold onto the substrate until the reaction is over. The active site brings about changes in the substrate, which leads to the formation of the product. To date, only the active site, has been explored. But, is it only the active site contributing to the enzyme activity?

The new technology – HT-MEK:

 HT-MEK is the successful result of the many trials conducted, to study parts of an enzyme beyond the active site. Two concepts are behind this new development.

  1. Microfluidics: large spaces are reduced to small ones to carry out fluidic experiments. It is similar to the mechanism of integrated circuits.
  2. Cell-free protein synthesis: here, only the parts needed to generate a protein are extracted and put together into a soupy extract. This soupy extract put into small wells formed (adjacent to each other) through microfluidics will be used to generate an ENZYME.

By combining, the two technologies, many variants of the same enzyme can be generated and studied side by side. Its function is analyzed by producing mutations in it. HT-MEK also helps to analyze regions other than the active site, whether other parts contribute to the enzymatic activity.

HT-MEK was implemented on PafA, an enzyme that is well studied. Researchers did find evidence to support that there are regions beyond the active site which contribute to catalysis. They also found that many of the applied mutations resulted in misfolds. The misfolds lead to an alternate structure, which hampered catalytic function, proving that structure is crucial to enzyme activity.

Conclusion:

There are many advantages of HT-MEK. Further studies, must be initiated and, must be accepted widely. HT-MEK could provide us with a whole new set of information concerning an enzyme’s mechanism. It could help with ALLOSTERIC TARGETING, a technique to increase drug specificity. It can be used to reverse engineer enzymes to generate new enzymes. Like, we could produce enzymes that could degrade plastics using HT-MEK. This new development could change our understanding of an enzyme so, further studies must be encouraged.

Also read: Extreme heat increases tree mortality in the sub-alpine forest

References: Markin, C. J., et al. “Revealing Enzyme Functional Architecture via High-Throughput Microfluidic Enzyme Kinetics.” Science, vol. 373, no. 6553, July 2021. science.sciencemag.org, doi:10.1126/science.abf8761. https://science.sciencemag.org/content/373/6553/eabf8761

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Related

Tagged active site binding site cell free protein synthesis Enzyme High throughput microfluidic enzyme kinetics microfluidics misfolds

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

First interchangeable biosimilar insulin for diabetic patients

bioxone August 2, 2021

Komal Bavaskar, Mumbai university Diabetes affects around 422 million people globally, with the majority residing in low- and middle-income countries, and diabetes is directly responsible for 1.6 million mortality per year. Diabetes has already been diagnosed in over 30 million people in India. What is diabetes? It is a metabolic disorder that results in elevated […]

First interchangeable

Related Post

  • BiotechToday
  • World

Chronic lung diseases patients are “primed” for severe Coronavirus infections

bioxone July 28, 2021July 27, 2021

Richa Prakash, MSc, Central University of Punjab The whole globe is aware of SARS-CoV-2 as it has infected tens of millions of people worldwide in the first nine months of 2020 making it a deadly pandemic. Along with other comorbidities, people with a history of chronic lung diseases (CLDs) like chronic obstructive pulmonary disease (COPD) […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

Deforestation causes anthropogenic insect wing polymorphism

BioTech Today August 24, 2021August 23, 2021

Varuni Ankolekar, Quartesian Human activities have led to concerns like climate change, global warming, etc. This is caused due to the increased use of fossil fuels, deforestation, and many more reasons. Severe forest degradation is caused due to agriculture, unsustainable forest management, mining, public service projects, and increased wildfire, etc. Loss of forest habitats may […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • BiotechToday
  • World

A potential Covid vaccine for Multiple Myeloma Patients

BioTech Today July 4, 2021July 4, 2021

Saptaparna Dasgupta, Bennett University The risk of COVID19 infection is exceeded in multiple myeloma patients. Vaccine for the general population with BNT162b2 mRNA COVID19 (BNT162b2) provides effective protection against COVID19. However, their efficacy on patients with multiple myeloma may be adversely affected by and not yet assessed due to factors related to disease and therapy. […]

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy